Clinical trials: Graft-vs-host Disease
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
Graft vs Host Disease, Hematologic Neoplasm
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
Bone marrow transplants (BMT) are one of the accepted therapies used to treat leukemia. However, BMT have risks of complications. One potentially life-threatening complication is known as graft-versus-host disease (GVHD).
- Conditions
- Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma
- Trial name
- NCT00001623
- Testing
- Allogeneic Bone Marrow Transplant
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Complex Regional Pain Syndromes, CRPS
Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)
The purpose of this study is to determine whether application of low dose Delta9-Tetrahydrocannabinol can prevent the development of chronic pain in patients with acute CRPS.
- Trial name
- NCT00377468
- Testing
- Delta9-Tetrahydrocannabinol
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)
PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood
In this prospective study is to examine whether the use of everolimus in patients after allogeneic SCT as part of GVHD prophylaxis for a further review in clinical studies is appropriate.
- Trial name
- NCT01509560
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Graft-Versus-Host Disease
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
To test a new agent, LBH589, in combination with glucocorticoids as initial therapy of acute graft versus host disease (GVHD).
- Trial name
- NCT01111526
- Testing
- Panobinostat (LBH589)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute GVH Disease
MTX and Steroid as First-line Therapy for aGVHD
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation…
- Trial name
- NCT04960644
- Testing
- MTX, Corticosteroid
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Peking University People's Hospital
Liver Transplant
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Assuming greater efficacy in the prevention of acute rejection in the EVR arm with minimisation of TAC levels, the hypothesis of the present trial was that the introduction of EVR in combination with the minimisation of TAC…
- Trial name
- REDUCE (NCT02040584)
- Testing
- Minimisation of TAC, TAC + MMF + corticosteroids
- Where
- 20 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Oral Chronic Graft vs Host Disease
Clobetasol for Oral Graft-Versus-Host Disease
Background: Oral graft-versus-host disease (GVHD) is a possible complication of bone marrow transplants. It is the result of the donor cells trying to attack the recipients body.
- Trial name
- NCT01557517
- Testing
- Clobetasol Oral Rinse
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Otitis Media, Age Determined Bacteria
Bacterial Assessment of Middle Ear Fluid in Children Undergoing Ventilation Tube Placement Surgery
Children with chronic otitis media have more resistant bacteria that require surgical intervention to eradicate the infections. The study will evaluate the dominant bacteria and their sensitivities to antibiotics.
- Trial name
- NCT01157910
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hillel Yaffe Medical Center
Graft Versus Host Disease, JNS Kinase
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
Background: About half the people who have a hematopoietic stem cell transplant using donor cells get Chronic Graft Versus Host Disease (cGVHD). This is chronic graft versus host disease.
- Conditions
- Graft Versus Host Disease, JNS Kinase, Topical Administration
- Trial name
- NCT03395340
- Testing
- Ruxolitinib 1.5% cream, vehicle cream
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Chronic Graft-Versus-Host Disease
A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
There is a clear need for effective, steroid-sparing agents for the management of chronic graft-versus-host disease (GVHD). Thus, agents like Histone deacetylase (HDAC) inhibitors, with the potential of decreasing…
- Trial name
- NCT01028313
- Testing
- LBH589, Methylprednisolone
- Where
- United States
- Sponsor
- SCRI Development Innovations, LLC
Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
- Conditions
- Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral
- Trial name
- NCT01155817
- Testing
- Nilotinib
- Where
- 5 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Stanford University
Leukemia, Lymphoma
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Primary Objective: 1. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context of unrelated donor and one…
- Trial name
- NCT00506922
- Testing
- Pentostatin, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Graft -Versus-host-disease
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
This is a randomized, multisite, Phase II study designed to compare the 1-year GVHD-free survival of the control arm (no axatilimab) to the experimental arm (axatilimab) after myeloablative allogeneic HCT.
- Trial name
- ABRAXAS (NCT07808112)
- Testing
- Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Medical College of Wisconsin
Spinal Cord Injury, Chronic
taVNS During Exercise and Recovery in Chronic Spinal Cord Injury
This study investigates the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on autonomic cardiovascular regulation during exercise and recovery in individuals with chronic spinal cord injury (SCI).
- Trial name
- taVNS-HRV-SCI (NCT07524491)
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- University of the Balearic Islands
Graft Versus Host Disease
Study of MEDI 507 in the Treatment of Pediatric Patients
To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.
- Trial name
- Pediatric GvHD (NCT00813618)
- Testing
- MEDI-507
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- MedImmune LLC
Myeloid Leukemia, Chronic
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
The first purpose of this study is to evaluate the persistence of the complete molecular remission in patients with Chronic Myeloid Leukemia after stopping imatinib treatment (determine by Reverse Transcription real-time…
- Trial name
- STIM (NCT00478985)
- Testing
- Imatinib ending
- Where
- 24 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.